Celularity Inc. (CELU), a biotechnology company developing cellular therapies, exhibits significant Shariah non-compliance primarily due to excessive debt levels (144.96% of market cap) and high interest income (36.03% of revenue). While its core business in regenerative medicine aligns with Islamic principles of health advancement, financial screening fails across AAOIFI, MSCI, and S&P standards. No inclusion in major Shariah indices confirms non-compliance status. Purification at 36.03% is required for any dividends, but structural debt issues pose ongoing risks. Investors should monitor for refinancing toward Islamic structures.